Paper Details

  1. Home
  2. Paper Details

Extended-release dexmethylphenidate 30 mg/d versus 20 mg/d: duration of attention, behavior, and performance benefits in children with attention-deficit/hyperactivity disorder.

Author: BramsMatthew, McCagueKevin, MunizRafael, PestreichLinda, SilvaRaul R

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Dexmethylphenidate extended-release (D-MPH-ER) 30 mg was more effective than D-MPH-ER 20 mg in improving attention, behavior, and performance in children with attention-deficit/hyperactivity disorder (ADHD) at later time points in the day. Both doses were more effective than placebo.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: This study aimed to compare the effects of dexmethylphenidate (D-MPH) extended-release (ER) 30 mg and D-MPH-ER 20 mg on attention, behavior, and performance in children with attention-deficit/hyperactivity disorder. METHODS: In a randomized, double-blind, 3-period-by-3-treatment, crossov...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/23860345

データ提供：米国国立医学図書館（NLM）

Dexmethylphenidate: A Dose-Dependent Oasis in the Desert of ADHD

The landscape of [attention-deficit/hyperactivity disorder (ADHD)] can be a challenging desert, with many individuals struggling to manage their symptoms and achieve their full potential. This research, like a seasoned guide leading a caravan through this arid terrain, explores the effectiveness of [dexmethylphenidate (D-MPH) extended-release (ER)] in treating ADHD. The study, conducted as a [randomized, double-blind, crossover trial], aimed to compare the effects of different doses of D-MPH-ER on [attention, behavior, and performance] in children with ADHD.

D-MPH-ER: Finding the Right Dose in the Desert of ADHD

The study found that [D-MPH-ER 30 mg/d was superior to D-MPH-ER 20 mg/d at later time points in the day], suggesting that [higher doses may be more effective later in the day]. This finding is like discovering a hidden oasis in the desert, offering a potential solution for managing the symptoms of ADHD throughout the day. The study also found that [both doses of D-MPH-ER were superior to placebo at all time points], further supporting the effectiveness of this medication for ADHD.

Navigating the Desert of ADHD with D-MPH-ER

This research highlights the importance of finding the right dose of medication for individuals with ADHD. Just as a camel adapts to the desert environment, we must continue to explore and utilize different strategies to manage this challenging condition. Remember, the desert of ADHD can be vast and complex, and finding the right tools and techniques for managing the disease is essential for well-being.

Dr.Camel's Conclusion

This research provides valuable insights into the dose-dependent effects of dexmethylphenidate extended-release in children with ADHD. The findings suggest that higher doses may be more effective later in the day, offering a potential solution for managing the symptoms of ADHD throughout the day. Like a camel navigating the shifting sands of the desert, researchers continue to adapt and seek new solutions to combat the challenges of ADHD.

Date :
  1. Date Completed 2014-02-26
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

23860345

DOI: Digital Object Identifier

00002826-201307000-00004

Related Literature

Article Analysis
・Effects of dexmethylphenidate
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.